Navigation Links
Newfound roadblock to interferon effectiveness against malignant melanoma

Researchers have uncovered a significant contributing factor to interferon resistance of malignant melanoma cells. The finding represents a step forward in understanding the molecular events that govern the growth of this type of cancer and the changes in gene expression and cellular signaling that underlie resistance to established therapies.

Malignant melanoma is the deadliest form of skin cancer, and if not treated successfully, it can spread to affect the liver, lungs, or brain. Chemotherapy fights the disease with limited efficiency, and the use of interferon has become the most established immunotherapy for advanced-stage melanoma. However, melanoma tumors often develop a resistance to the drug, posing one of the major obstacles in the clinical treatment of this cancer.

Now Professor Manfred Schartl and Dr. Claudia Wellbrock, scientists at the University of W�rzburg, believe they have an explanation for how this interferon resistance is acquired. They have found that when a gene called STAT5 is too active in melanoma cells, it can counteract the anti-cancer effect of interferon. Interferon normally impedes the growth of cancer cells, whereas STAT5 is thought to act to promote cellular growth.

The new work, published by Professor Schartl and his colleagues in Current Biology, shows that interferon actually activates STAT5 in melanoma cells but that under normal conditions, this does not interfere with the inhibitory potential of the drug. However, when cancer cells posses too much STAT5 activity to begin with, the further activation of STAT5 function by interferon induces a mechanism that blocks the ability of the drug to effectively inhibit growth.

Confirming this initial finding, the researchers found that when they inhibited STAT5 in interferon-resistant melanoma cells, they were able to restore the effectiveness of interferon. This demonstrates the relevance of STAT5 and its contribution to the behavior of melanoma cells in th e late stage of the disease.

The findings explain the frequent failure of interferon therapies and thus further our understanding of melanoma in its late, and most aggressive, stage. In the future, a routine analysis of the STAT5 status in melanoma patients might help to improve and personalize therapies.


Source:Cell Press

Related biology news :

1. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
2. Greasing interferons gears may pave way to greater therapeutic benefits, fewer side effects
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Man-made wetlands effectiveness similar to natural marsh
5. UCLA study assesses cost-effectiveness of Hepatitis B drugs
6. Structures of marine toxins provide insight into their effectiveness as cancer drugs
7. Test reveals effectiveness of potential Huntingtons disease drugs
8. Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness
9. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
10. Bound for destruction: Ubiquitination protects against improper Notch signaling
11. Female sex hormones play a vital role in defense against sexually transmitted diseases
Post Your Comments:

(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: ... to provide their customers enhanced security to access ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... NEWPORT BEACH, Calif. , June 23, 2016 /PRNewswire/ ... offering new biological discoveries to the medical community, has ... and co-founder Matthew Nunez . "We ... provide us with the capital we need to meet ... funding will essentially provide us the runway to complete ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
Breaking Biology Technology: